<SEC-DOCUMENT>0001019056-22-000371.txt : 20220506
<SEC-HEADER>0001019056-22-000371.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505170032
ACCESSION NUMBER:		0001019056-22-000371
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20220502
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		22897457

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>modular_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:MODD="http://modular-medical.com/20220502">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_MODD_modular%2Dmedical.com_20220502 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20220502_20220502 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20220502.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-05-02to2022-05-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-02</xbrli:startDate>
        <xbrli:endDate>2022-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES</b></span><br />
<span style="font-size: 14pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></span><br />
<span style="font-size: 12pt"><b>Washington, D.C. 20549</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 20%; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_906_edei--DocumentType_c20220502__20220502_zH65NKbVC9M6"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>CURRENT REPORT<br />Pursuant to Section 13 or 15(d) of the<br />Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">Date of Report (Date of earliest event reported):&#160;&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; width: 99%; font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--DocumentPeriodEndDate_c20220502__20220502_ztNJsJAN7079"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 2, 2022</ix:nonNumeric></span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 24pt"><b><span id="xdx_904_edei--EntityRegistrantName_c20220502__20220502_zAxd8joyrUj5"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Exact name of registrant as specified in its charter)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220502__20220502_z87kZKaKOqxj"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20220502__20220502_zvSuUm4ZEXO3"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityFileNumber">001-41277</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220502__20220502_zQYcPrDIrL73"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 1pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 1pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br />of incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Commission<br />File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(IRS Employer<br />Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 48%; font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220502__20220502_zJ4vu8lZsTpg"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityAddressAddressLine1">16772 W. Bernardo Drive</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20220502__20220502_z6RHIamLZ55j"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20220502__20220502_zyA5Db8XQeB4"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 48%; font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220502__20220502_zAQugNZWo5ag"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">Registrant&#8217;s telephone number, including area code:&#160;&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; width: 99%; font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--CityAreaCode_c20220502__20220502_zglNE83dG2I9"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:CityAreaCode">(858)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20220502__20220502_zbQCthMKYo4j"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Former name or former address, if changed since last report)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_908_edei--WrittenCommunications_c20220502__20220502_zPxy9GBK928e"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleanfalse" name="dei:WrittenCommunications">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20220502__20220502_zdFkpuIi6Z65"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleanfalse" name="dei:SolicitingMaterial">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20220502__20220502_z495qtMgl4Ie"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20220502__20220502_zQ0DrEIxUZ34"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0; text-indent: 0"><span style="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 40%; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: Black 1pt solid; width: 20%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Trading symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; width: 40%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20220502__20220502_zZRKdEc25tdh"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220502__20220502_zKNTEsolkx9k"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20220502__20220502_zacwBn9oVgIh"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span> </span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 27.35pt; text-align: right; text-indent: -27.35pt"><span style="font-size: 10pt">&#160;</span>Emerging growth company <span style="font-family: Wingdings"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20220502__20220502_zzrazzK6Y2qc"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0in"><span style="font-size: 10pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_909_edei--EntityExTransitionPeriod_c20220502__20220502_zxNswKvtgoS3"><ix:nonNumeric contextRef="From2022-05-02to2022-05-02" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">o</ix:nonNumeric></span></span></span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 0pt"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->
<!-- Field: Page; Sequence: 1 -->
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On May 2, 2022, Modular Medical, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with Sio Capital Management, an institutional investor (the &#8220;Investor&#8221;), pursuant to which the Company agreed to sell, in a registered direct offering (the &#8220;Registered Offering&#8221;), an aggregate of 449,438 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a purchase price per Share of $4.45 and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of 1,348,314 shares of Common Stock at a purchase price per Pre-Funded Warrant of $4.44. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In a concurrent private placement (the &#8220;Private Placement&#8221; and together with the Registered Offering, the &#8220;Offerings&#8221;) under the Purchase Agreement, the Company issued to the Investor warrants (the &#8220;Private Placement Warrants&#8221;) to purchase an aggregate of 1,438,202 shares of Common Stock at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable six months from date of issuance and have a five-year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Investor (together with its affiliates) will not be able to exercise any portion of the Pre-Funded Warrants or Private Placement Warrants to the extent that the Investor would own more than 9.99% of the Company&#8217;s outstanding Common Stock immediately after exercise. Pursuant to the terms of the Purchase Agreement, the Company agreed to cause a registration statement on Form S-1 providing for the resale by holders of shares of its Common Stock issuable upon the exercise of the Private Placement Warrants, to be filed within 30 days of the Offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The closing of the sales of these securities under the Purchase Agreement is expected to occur on or about May 5, 2022, subject to customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Oppenheimer &amp;
Co. Inc. is acting as the sole placement agent (the &#8220;Placement Agent&#8221;) for the Company, on a &#8220;reasonable best efforts&#8221; basis, in
connection with the Offerings. The Placement Agent will be entitled to a cash fee of 6.0% of the aggregate gross proceeds of the
Registered Offering and the reimbursement of certain out-of-pocket expenses up to $75,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The net proceeds to the Company from the Registered Offering, after deducting the Placement Agent&#8217;s fees and expenses but before paying the Company&#8217;s estimated offering expenses, are expected to be approximately $7.4 million. The Company intends to use the net proceeds from the Registered Offering for general corporate purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the Purchase
Agreement, except with respect to certain exempt issuances, the Company is prohibited from issuing common stock or common
stock equivalents for 90 days after the closing and from engaging in certain variable rate transactions for a period of six months
from the closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Shares and Pre-Funded Warrants were offered and sold by the Company pursuant to a prospectus supplement which was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May 4, 2022, under the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-264193), which was declared effective by the SEC on April 19, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The forms of the Pre-Funded
Warrant, the Private Placement Warrant and the Purchase Agreement are filed as Exhibits 4.1, 4.2 and 10.1, respectively, to this
Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by,
such documents, which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The legal opinion and consent of Lucosky Brookman LLP relating to the securities is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 3.02.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Unregistered Sales of Equity Securities.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The applicable information
set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The shares of common stock
underlying the Private Placement Warrants were not registered under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), but qualified for exemption under Section 4(a)(2) and/or Regulation D of the Securities Act. The securities were exempt
from registration under Section 4(a)(2) of the Securities Act because the issuance of such securities by the Company did not involve
a &#8220;public offering,&#8221; as defined in Section 4(a)(2) of the Securities Act, due to the insubstantial number of persons involved
in the transaction, size of the offering, manner of the offering and number of securities offered. The Company did not undertake an offering
in which it sold a high number of securities to a high number of investors. In addition, the Investor had the necessary investment intent,
as required by Section 4(a)(2) of the Securities Act since the Investor agreed to, and received, the securities bearing a legend stating
that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would
not be immediately redistributed into the market and therefore not be part of a &#8220;public offering.&#8221; Based on an analysis of
the above factors, the Company has met the requirements to qualify for exemption under Section 4(a)(2) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 8.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Other Events.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On May 3, 2022, the Company issued a press release announcing the Offerings. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt">Exhibits:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex4_1.htm">Form of Pre-Funded Warrant</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex4_2.htm">Form of Private Placement Warrant</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex5_1.htm">Opinion of Lucosky Brookman LLP</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex10_1.htm">Form of Securities Purchase Agreement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex99_1.htm">Press Release, dated May 3, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
</table>
<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>MODULAR MEDICAL, INC.</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 42%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Date: May 5, 2022</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">By:&#160;&#160;</span></td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/ James Besser</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">James Besser</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
</table>

    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZl/5MddOlRUWsIqWI28FGGWwnJTP+9Eje0rFFDIEkvPflCRGKNa10iwynRVVCjV3fKodQ4QUZzRm9o9hsc/Czwqu2jpVx4/kDC/IMemYepVJ5YbQ+tMUmh2QeJ7NYSr/kWQaHnQi+ekHmohs0TqsWlGngwNSzRqd4mD7U6kWGumGMOiJbTSaHNEom+Q0ySSXs6aGexDcLZVmIIBwrEGume/+NuVtHHSxb7HyWndB/Bx8WeElH -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4_1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PREFUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>MODULAR
MEDICAL, INC.</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrant
    Shares: [___________]</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Initial
    Exercise Date:&nbsp;________________</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">THIS
PREFUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [PURCHASER] or
its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this
Warrant is exercised in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from
Modular Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to [___________] shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section
1</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act. A Person shall be regarded
as in control of the Company if the Company owns or directly or indirectly controls more than fifty percent (50%) of the voting
stock or other ownership interest of the other person, or if it possesses, directly or indirectly, the power to direct or cause
the direction of the management and policies of such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink
Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market
value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg determined as of the day immediately following the first public announcement of the applicable Change of
Control, or, if the Change of Control is not publicly announced, the date the Change of Control is consummated, for pricing purposes
and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term
of this Warrant as of such date of request, (ii) an expected volatility equal to 100% (iii) the underlying price per share used
in such calculation shall be the greater of (a) the highest Weighted Average Price during the five (5) Trading Days prior to the
closing of the Change of Control and (b) the sum of the price per share being offered in cash, if any, plus the value of any non-cash
consideration, if any, being offered in such Change of Control, (iv) a zero cost of borrow and (v) a 360 day annualization factor.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;&ldquo;<U>Change
of Control</U>&rdquo; means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification
of the Common Stock in which holders of the Company&rsquo;s voting power immediately prior to such reorganization, recapitalization
or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities
and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities
with the authority or voting power to elect the members of the board of directors (or their equivalent if other than a corporation)
of such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant to a migratory merger
effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a merger in connection with
a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly or indirectly, by the
Company in such acquisition is not greater than 20% of the Company&rsquo;s market capitalization as calculated on the date of
the consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority of the board of
directors of the Company. Notwithstanding anything herein to the contrary, any transaction or series of transaction that, directly
or indirectly, results in the Company or the Successor Entity not having Common Stock or common stock, as applicable, registered
under the 1934 Act and listed on an Eligible Market shall be deemed a Change of Control.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such shares of common stock may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Eligible
Market</U>&rdquo; means The Nasdaq Capital Market, the NYSE American LLC, The Nasdaq Global Select Market, The Nasdaq Global Market
or The New York Stock Exchange, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Fundamental
Transaction</U>&rdquo; means (A) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or
otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving
corporation) another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of
the properties or assets of the Company or any of its &ldquo;significant subsidiaries&rdquo; (as defined in Rule 1-02 of Regulation
S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be
subject to or have its shares of Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender
or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50%
of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party
to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding;
or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject
Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule
13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at
least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as
if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making
or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of
Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934
Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its shares of Common
Stock, (B) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or
more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the
&ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition,
purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation,
business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification
or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued
and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding
shares of Common Stock not held by all such Subject Entities as of the Subscription Date calculated as if any shares of Common
Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented
by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities
to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their Common
Stock without approval of the stockholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates
or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured
in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct
this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument
or transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Successor
Entity</U>&rdquo; means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or Change of Control or one or more Person or Persons (or, if so elected
by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction or Change of Control shall have been
entered into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Colonial Stock Transfer Company, Inc., the current transfer agent of the Company, and any successor transfer
agent of the Company.</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink
Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market
value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other prefunded Common Stock purchase warrants issued by the Company pursuant to the Securities Purchase
Agreement, dated as of May 2, 2022, by and between the Company and Oppenheimer &amp; Co. Inc. as Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section
2</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise, required to be paid by the Holder
pursuant to Section 2(d)(vi) herein, by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of
Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days
of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in
purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice.&nbsp;<B>The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof unless such Warrant is surrendered to the Company and reissued
to the Holder pursuant to Section 2(d)(ii).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.01 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal
exercise price of $0.01 per Warrant Share) shall be required to be paid by the Holder to the Company to effect any exercise of
this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise
price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior
to the Termination Date. The remaining unpaid exercise price per Warrant Share shall be $0.01, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. This Warrant may be exercised, in whole or in part, at any time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-size: 10pt">(A)
= &nbsp;as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if
such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day
or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
(ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time
of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the
close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of
the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both
executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">(B)
= &nbsp;&nbsp;the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-size: 10pt">(X)
= &nbsp;the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this
Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised. The Company agrees
not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">i.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Warrant Shares Upon Exercise</U>. The Company
shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or
(B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the
earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after
delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record
of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the
Company within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant
Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock
on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in
the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with
respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with
respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, the
Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise
Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder.</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect
of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the
Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than
the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of
any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section
3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>,&nbsp;<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any
such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of
such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder
until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity assumes
in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e), including
agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding
number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant
(without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments
to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this
Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the consummation of each Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of the applicable Fundamental
Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer
instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon
consummation of each Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be
issued upon exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction, in lieu of
the shares of Common Stock (or other securities, cash, assets or other property (except such items still issuable pursuant to
the terms herein, which shall continue to be receivable thereafter)) issuable upon the exercise of this Warrant prior to the applicable
Fundamental Transaction, such shares of common stock (or its equivalent) of the Successor Entity which the Holder would have been
entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior
to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant), as adjusted in
accordance with the provisions of this Warrant. Notwithstanding the foregoing, and without limiting Section 2(e) hereof, the Holder
may elect, at its sole option, by delivery of written notice to the Company to waive this Section 3(e) to permit the Fundamental
Transaction without the assumption of this Warrant. In addition to and not in substitution for any other rights hereunder, prior
to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive
securities or other assets with respect to or in exchange for shares of Common Stock (a &ldquo;<B>Corporate Event</B>&rdquo;),
the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise
of this Warrant at any time after the consummation of the applicable Fundamental Transaction, in lieu of the shares of the Common
Stock (or other securities, cash, assets or other property (except such items still issuable pursuant to the terms herein, which
shall continue to be receivable thereafter)) issuable upon the exercise of the Warrant prior to such Fundamental Transaction,
such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription
rights) (collectively, the &ldquo;<B>Corporate Event Consideration</B>&rdquo;) which the Holder would have been entitled to receive
upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable
Fundamental Transaction (without regard to any limitations on the exercise of this Warrant). The provision made pursuant to the
preceding sentence shall be in a form and substance reasonably satisfactory to the Holders. The provisions of this Section 3(e)
shall apply similarly and equally to successive Fundamental Transactions and Corporate Events. Notwithstanding the foregoing,
in the event of a Change of Control, at the request of the Holder delivered before the 30th day after such Change of Control,
the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business
Days after such request (or, if later, on the effective date of the Change of Control), an amount equal to the Black Scholes Value
of the remaining unexercised portion of this Warrant on the effective date of such Change of Control, payable in cash; provided,
however, that, if the Change of Control is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s
Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of consummation
of such Change of Control, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of
the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Change of Control, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Change
of Control; provided, further, that if holders of Common Stock are not offered or paid any consideration in such Change of Control,
such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which entity may be the Company
following such Change of Control) in such Change of Control.</FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.65in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its subsidiaries) is
a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register
of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section
4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer
of Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which
the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial
Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section
5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall
the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1in; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of Section 3, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or
any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of the Company&rsquo;s assets, or any compulsory
share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it
is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>MODULAR
    MEDICAL, inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TO:
MODULAR MEDICAL, inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase [XX] Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">[
] if permitted, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)&nbsp;&nbsp;&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Warrant
Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 27%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Investing Entity:</FONT></TD>
    <TD STYLE="width: 73%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Signature
    of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="width: 97%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 12%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 52%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4_2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>MODULAR
MEDICAL, INC.</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 51%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Warrant Shares: _______</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">Issue Date:&nbsp;&nbsp;May
    5, 2022</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after [ ]1 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the five
year anniversary of the Initial Exercise date, provided, however, if such date is not a Trading Day, the immediately following
Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Modular Medical,
Inc., a company incorporated under the laws of Nevada (the &ldquo;<U>Compan</U>y&rdquo;), up to [&bull;] shares (as subject to
adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock
under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
1. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase A</U>g<U>reement</U>&rdquo;), dated May [2], 2022, among the Company and
the purchasers signatory thereto.</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">1 <U>Note</U>: Insert date
that is 6 months from the issuance date.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
2. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of
a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed
hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is
delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $6.60, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. Notwithstanding anything contained herein to the contrary, if a registration statement (which may be the Registration
Statement) covering the issuance or resale of the Warrant Shares is not available for the issuance or resale, as applicable, of
such Warrant Shares, the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making
the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price,
elect instead to receive upon such exercise the &ldquo;Net Number&rdquo; of shares of Common Stock determined according to the
following formula (a &ldquo;<B>Cashless Exercise</B>&rdquo;):</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 21%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Net Number
    =</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(A x B)
    - (A x C)</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">For purposes
of the foregoing formula:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">A = the
    total number of shares with respect to which this Warrant is then being exercised.&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">B = as applicable:
    (i) the Weighted Average Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Exercise
    Notice if such Exercise Notice is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading
    Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of &ldquo;regular
    trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such
    Trading Day, (ii) at the option of the Holder, either (y) the Weighted Average Price on the Trading Day immediately preceding
    the date of the applicable Exercise Notice or (z) the Bid Price of the Common Stock as of the time of the Holder&rsquo;s execution
    of the applicable Exercise Notice if such Exercise Notice is executed during &ldquo;regular trading hours&rdquo; on a Trading
    Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
    hours&rdquo; on a Trading Day) pursuant to Section 1(a) hereof or (iii) the Weighted Average Price of the Common Stock on
    the date of the applicable Exercise Notice if the date of such Exercise Notice is a Trading Day and such Exercise Notice is
    both executed and delivered pursuant to Section 1(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such
    Trading Day.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">C = the Exercise Price
    then in effect for the applicable Warrant Shares at the time of such exercise.</FONT></TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a
Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a
Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to
which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1)
Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share
Deliver</U>y<U> Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of
a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to
the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the
Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per
Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights
available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance
with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after
such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares
which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash
to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scri</U>p. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses
shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; <U>provided</U>,<U> however</U>, that, in the event that Warrant Shares are to be issued in a name
other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached
hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of
any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall
not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving
effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section
2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
3. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Ri</U>g<U>hts</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right
to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a
record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that
the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held
in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity assumes
in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d), including
agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding
number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant
(without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments
to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this
Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the consummation of each Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of the applicable Fundamental
Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer
instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon
consummation of each Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be
issued upon exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction, in lieu of
the shares of Common Stock (or other securities, cash, assets or other property (except such items still issuable pursuant to
the terms herein, which shall continue to be receivable thereafter)) issuable upon the exercise of this Warrant prior to the applicable
Fundamental Transaction, such shares of common stock (or its equivalent) of the Successor Entity which the Holder would have been
entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior
to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant), as adjusted in
accordance with the provisions of this Warrant. Notwithstanding the foregoing, and without limiting Section 2(d) hereof, the Holder
may elect, at its sole option, by delivery of written notice to the Company to waive this Section 3(d) to permit the Fundamental
Transaction without the assumption of this Warrant. In addition to and not in substitution for any other rights hereunder, prior
to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive
securities or other assets with respect to or in exchange for shares of Common Stock (a &ldquo;<B>Corporate Event</B>&rdquo;),
the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise
of this Warrant at any time after the consummation of the applicable Fundamental Transaction but prior to the Expiration Date,
in lieu of the shares of the Common Stock (or other securities, cash, assets or other property (except such items still issuable
pursuant to the terms herein, which shall continue to be receivable thereafter)) issuable upon the exercise of the Warrant prior
to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants
or other purchase or subscription rights) (collectively, the &ldquo;<B>Corporate Event Consideration</B>&rdquo;) which the Holder
would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised
immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant).
The provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holders.
The provisions of this Section 3(d) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.
Notwithstanding the foregoing, in the event of a Change of Control, at the request of the Holder delivered before the 30th day
after such Change of Control, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the
Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Change of Control), an amount
equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the effective date of such Change of
Control, payable in cash; provided, however, that, if the Change of Control is not within the Company&rsquo;s control, including
not approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor
Entity, as of the date of consummation of such Change of Control, the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common
Stock of the Company in connection with the Change of Control, whether that consideration be in the form of cash, stock or any
combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Change of Control; provided, further, that if holders of Common Stock are not offered or paid any consideration
in such Change of Control, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
entity may be the Company following such Change of Control) in such Change of Control.</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section
3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such
adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring
such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or
any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of the Company&rsquo;s assets, or any compulsory
share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it
is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
4. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferabilit</U>y. Subject to compliance with any applicable securities laws and the conditions set forth in Section
4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender
this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Re</U>g<U>ister</U>. The Company shall register this Warrant, upon records to be maintained by the Company for
that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company
may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this
Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under
the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale
restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing
such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of
the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring
this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
5. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section
2(d) (i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless
exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein,
in no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating
to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which,
in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or
stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated
as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from
its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon
the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise
of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by
this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal
securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without
limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees,
including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liabilit</U>y. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise
to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to
time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
6. Certain Definitions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
&ldquo;<B>Affiliate</B>&rdquo; means, with respect to any Person, any other Person that directly or indirectly controls, is controlled
by, or is under common control with, such Person, it being understood for purposes of this definition that &ldquo;control&rdquo;
of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the
election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by
contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
&ldquo;<B>Black Scholes Value</B>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from
the &ldquo;OV&rdquo; function on Bloomberg determined as of the day immediately following the first public announcement of the applicable
Change of Control, or, if the Change of Control is not publicly announced, the date the Change of Control is consummated, for pricing
purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term
of this Warrant as of such date of request, (ii) an expected volatility equal to 100% (iii) the underlying price per share used in such
calculation shall be the greater of (a) the highest Weighted Average Price during the five (5) Trading Days prior to the closing of the
Change of Control and (b) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration,
if any, being offered in such Change of Control, (iv) a zero cost of borrow and (v) a 360 day annualization factor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
&ldquo;<B>Change of Control</B>&rdquo; means any Fundamental Transaction other than (i) any reorganization, recapitalization or
reclassification of the Common Stock in which holders of the Company&rsquo;s voting power immediately prior to such reorganization,
recapitalization or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly
traded securities and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving
entity (or entities with the authority or voting power to elect the members of the board of directors (or their equivalent if
other than a corporation) of such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant
to a migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a
merger in connection with a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly
or indirectly, by the Company in such acquisition is not greater than 20% of the Company&rsquo;s market capitalization as calculated
on the date of the consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority
of the board of directors of the Company. Notwithstanding anything herein to the contrary, any transaction or series of transaction
that, directly or indirectly, results in the Company or the Successor Entity not having Common Stock or common stock, as applicable,
registered under the 1934 Act and listed on an Eligible Market shall be deemed a Change of Control.</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
&ldquo;<B>Eligible Market</B>&rdquo; means The Nasdaq Capital Market, the NYSE American LLC, The Nasdaq Global Select Market,
The Nasdaq Global Market or The New York Stock Exchange, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
&ldquo;<B>Fundamental Transaction</B>&rdquo; means (A) that the Company shall, directly or indirectly, including through subsidiaries,
Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company
is the surviving corporation) another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially
all of the properties or assets of the Company or any of its &ldquo;significant subsidiaries&rdquo; (as defined in Rule 1-02 of
Regulation S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company
to be subject to or have its shares of Common Stock be subject to or party to one or more Subject Entities making, a purchase,
tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock,
(y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making
or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding;
or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject
Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule
13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at
least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as
if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making
or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of
Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934
Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its shares of Common
Stock, (B) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or
more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the
&ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition,
purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation,
business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification
or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued
and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding
shares of Common Stock not held by all such Subject Entities as of the Subscription Date calculated as if any shares of Common
Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented
by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities
to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their Common
Stock without approval of the stockholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates
or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured
in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct
this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument
or transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)
&ldquo;<B>Person</B>&rdquo; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity and a government or any department or agency thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)
&ldquo;<B>Successor Entity</B>&rdquo; means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent
Entity) formed by, resulting from or surviving any Fundamental Transaction or Change of Control or one or more Person or Persons
(or, if so elected by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction or Change of Control
shall have been entered into.</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>MODULAR MEDICAL, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MODULAR MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase _______ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in"><FONT STYLE="font-size: 10pt">[ ] in lawful money of
the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">[
] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">The Warrant Shares shall be
delivered to the following DWAC Account Number:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(4)&#9;<U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities
Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">[SIGNATURE OF HOLDER]</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Investing Entity:</FONT></TD>
    <TD STYLE="width: 77%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Signature
    of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="width: 96%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 18%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 52%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5_1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right; text-indent: 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><IMG SRC="modular001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">May 5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0"><FONT STYLE="font-size: 10pt">Modular Medical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0"><FONT STYLE="font-size: 10pt">16772 W. Bernardo Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">San Diego, California 92127</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>RE:</B></FONT></td>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Registration Statement on Form S-3 (333-264193)</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">We
have acted as counsel to you, Modular Medical, Inc., a Nevada corporation, (the &ldquo;<B>Company</B>&rdquo;) in connection with the
Company&rsquo;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
pursuant to the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;) (File No. 333-264193) (the &ldquo;<B>Registration
Statement</B>&rdquo;), and declared effective by the Commission on April 19, 2022 and the related prospectus therein dated April 19,
2022 (the &ldquo;<B>Base Prospectus</B>&rdquo;) and the prospectus supplement dated May 2, 2022 (the Base Prospectus and the Prospectus
Supplement, the &ldquo;<B>Prospectus</B>&rdquo;), relating to the offering by the Company of 449,438 shares (the &ldquo;<B>Shares</B>&rdquo;)
of the Company&rsquo;s common stock, par value $0. 001 per share (&ldquo;<B>Common Stock</B>&rdquo;), Pre-Funded Warrants (the &ldquo;<B>Pre-Funded
Warrants</B>&rdquo;) to purchase up to 1,348,314 shares of Common Stock, and warrants (the &ldquo;<B>Purchase Warrants</B>&rdquo;, and
together with the Pre-Funded Warrants the &ldquo;<B>Warrants</B>,&rdquo; and shares of Common Stock issuable upon the exercise of the
Warrants, the &ldquo;<B>Warrant Shares</B>&rdquo;) to purchase 1,438,202 shares of Common Stock. The Shares and Pre-Funded Warrants are
covered by the Registration Statement and Prospectus and we understand that the Shares and Warrants are to be offered and sold in the
manner described in the Prospectus. This opinion is being delivered at the request of the Company and in accordance with the requirements
of Item 601(b)(5) of Regulation S-K promulgated by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">In connection with this opinion, we have examined the originals or copies certified or otherwise identified to our satisfaction of the following: (a) Articles of Incorporation of the Company, as amended to date, (b) Bylaws of the Company, as amended to date, and (c) the Registration Statement, the Prospectus, and all exhibits thereto. In addition to the foregoing, we also have relied as to matters of fact upon the representations made by the Company and its representatives and we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to original documents of all documents submitted to us certified or photostatic copies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Based upon and subject to the foregoing, we are of the opinion that (i) the Shares have been duly authorized and, when issued and paid for as described in the Prospectus, will be validly issued, fully paid and non-assessable, (ii) when the Warrants are issued, delivered and paid for, such Warrants will be the legal binding obligations of the Company enforceable in accordance with their terms except (a) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at law), (b) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, (c) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought, and (d) we express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the Warrants, and (iii) upon exercise of the Warrants in accordance with their terms, the Warrant Shares will be validly issued, fully paid and non-assessable.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Our opinion is limited to the federal laws of the United States and Chapter 78 of the Nevada Revised Statutes. We express no opinion as to the effect of the law of any other jurisdiction. Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come to our attention. This opinion letter is limited to the laws in effect as of the date the Registration Statement is declared effective by the Commission and is provided exclusively in connection with the public offering contemplated by the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Our opinion letter is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Common Stock, Warrants, Warrant Shares, or the agreements and instruments addressed herein, or in the Registration Statement. This opinion is based upon currently existing statutes, regulations, rules and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">This opinion letter is furnished in connection with the filing of the Registration Statement and may not be relied upon for any other purpose without our prior written consent in each instance. Further, no portion of this letter may be quoted, circulated or referred to in any other document for any other purpose without our prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">We consent to the filing of this opinion with the SEC as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K filed on May 5, 2022 which is incorporated by reference in the Prospectus. We also consent to the reference of our firm under the caption &ldquo;Experts&rdquo; in the Prospectus and in each case in any amendment or supplement thereto. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 and Section 11 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder, nor do we admit that we are experts with respect to any part of the Prospectus within the meaning of the term &ldquo;expert&rdquo; as used in the Securities Act of 1933, as amended, or the related rules and regulations of the Securities and Exchange Commission promulgated thereunder.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very Truly Yours,</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.4pt"><FONT STYLE="font-size: 10pt">/s/<I>Lucosky
    Brookman LLP</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Lucosky Brookman LLP</FONT></td></tr>
</table>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10_1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 2, 2022, between Modular Medical, Inc.,
a company incorporated under the laws of Nevada (the &ldquo;<U>Compan</U>y&rdquo;), and each purchaser identified on the signature
pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under
the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) as to the Shares and the Pre-Funded Warrants
(each as defined herein) and (ii) an exemption from the registration requirements of Section 5 of the Securities Act contained
in Section 4(a)(2) thereof and/or Regulation D thereunder as to the Common Warrants, the Company desires to issue and sell to
each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company
as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
I</B></FONT><FONT STYLE="font-size: 10pt"><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the
following terms have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Da</U>y&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed
to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential
employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of
any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks
in The City of New York generally are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Closin</U>g&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)
the Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later
than the second (2nd) Trading Day following the date hereof (subject to such satisfaction or waiver).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Lucosky Bookman LLP, with offices located in Woodbridge, New Jersey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Company&rsquo;s
IP Counsel</U>&rdquo; means Schmeiser Olsen &amp; Watts LLP, with offices located in Carlsbad, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Common Warrants shall be exercisable at any time on or after the date that is six (6) months
from the date of issuance and have a term of exercise equal to five (5) years from the initial exercise date, in the form of <U>Exhibit
A </U>attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time)
and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed
between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York
City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose (b) securities upon the exercise or exchange of or conversion
of any Securities issued hereunder and any securities exercisable or exchangeable for or convertible into shares of Common Stock
issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this
Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such
securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company,
provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration
rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in
Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which
is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include
a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities, and (d) shares of Common Stock or options to consultants, provided that such securities are
issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit
the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a) herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Mintz</U>&rdquo;
means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located in New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Participation
Maximum</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(a).</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Oppenheimer &amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section&nbsp;2.2(a)&nbsp;hereof, in the form of&nbsp;<U>Exhibit&nbsp;B</U>&nbsp;attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Proceedin</U>g&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Purchaser
Part</U>y&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-264193 which registers the sale of
the Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Resale
Registration Statement</U>&rdquo; means a registration statement on Form S-1 covering the resale of the Common Warrant Shares
by each Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Common Warrants and the Common Warrant Shares.</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares, Pre-Funded Warrants and Common Warrants
purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading
&ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Subsidiar</U>y&rdquo;
means any subsidiary of the Company, and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, the Common Warrants, all exhibits and schedules thereto and
hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Transfer
A</U>g<U>ent</U>&rdquo; means Colonial Stock Transfer Company, Inc., the current transfer agent of the Company, with offices located
at 66 Exchange Place, 1st Floor, Salt Lake City, UT 84111, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in
interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
II</B></FONT><FONT STYLE="font-size: 10pt"><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees
to sell, and the Purchasers, severally and not jointly, agree to purchase, an aggregate of $[&#9;&#9;] of Shares, Pre-Funded Warrants
and Common Warrants as set forth on the signature page hereto. Each Purchaser&rsquo;s Subscription Amount as set forth on the
signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement
with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, Pre-Funded Warrants and a
Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in
Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the
Closing shall occur at the offices of Mintz or such other location as the parties shall mutually agree. Unless otherwise directed
by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released
by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares,
the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall
be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each
Purchaser and the Placement Agent the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a &ldquo;comfort letter&rdquo; from Farber Hass Hurley LLP in the form and substance reasonably satisfactory to the Purchasers
and the Placement Agent<FONT STYLE="background-color: white"> </FONT>(i)&nbsp;confirming that they are an independent registered
public accounting firm within the meaning of the Securities Act and the PCAOB, and (ii)&nbsp;stating, as of such date, the conclusions
and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&rsquo;
&ldquo;comfort letters&rdquo; to the Purchasers and the Placement Agent in connection with registered public offerings;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a legal opinion of Company Counsel, substantially in the form reasonably satisfactory to the Purchasers and the Placement
Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
legal opinion of the Company&rsquo;s IP Counsel, substantially in the form reasonably satisfactory to the Purchasers and the Placement
Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the
Chief Executive Officer or Chief Financial Officer;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via
The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) such amount of Shares as provided
on the Purchaser&rsquo;s signature page, attached hereto, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock as provided on the signature
page executed by the Purchaser attached hereto, with an exercise price equal to $6.60, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
Pre-Funded Warrant registered in the name of the Purchaser to purchase up to a number of shares of Common Stock as provided on
the signature page executed by the Purchaser, attached hereto, with an exercise price equal to $0.01 per share, subject to adjustment
therein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>such
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with
the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or
Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained
herein (unless as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall
have been performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions
being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or
Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company
contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or
the Company&rsquo;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported
by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose
trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the
United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or
other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial
market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the
Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
III</B></FONT><FONT STYLE="font-size: 10pt"><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties
to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Subsidiaries</U>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each
Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly
issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If
the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be
disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Or</U>g<U>anization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or
otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization,
with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.
Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles
of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified
to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature
of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect
on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations,
assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii)
a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has
been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and
authority or qualification.</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders
in connection herewith or therewith. This Agreement and each other Transaction Document to which it is a party has been (or upon
delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction
Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated
hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s
certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any
Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment,
anti-dilution, or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which
the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected,
or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities
laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case
of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order
of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents,
other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus
Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Shares, the Pre-Funded Warrant Shares
and the Common Warrant Shares for trading thereon in the time and manner required thereby, (iv) the filing of Form D with the
Commission and such filings as are required to be made under applicable state securities laws and (v) waiver from Oppenheimer
&amp; Co. Inc. in order to allow the Company to sell the Securities (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Issuance of the Securities; Registration</U>. The Securities are duly authorized, and, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all
Liens imposed by the Company. The Common Warrant Shares and Pre-Funded Warrant Shares, when issued in accordance with the terms
of the Common Warrants and the Pre-Funded Warrants, respectively, will be validly issued, fully paid and nonassessable, free and
clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number
of shares of Common Stock issuable pursuant to this Agreement, the Pre-Funded Warrants and the Common Warrants. The Company has
prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective
on April 19, 2022 (the &ldquo;<U>Effective Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto
as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and
no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of
the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge
of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall
file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto
conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3. The Company
is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market
value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth
in General Instruction I.B.6 of Form S-3.</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports. The
Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock
(the &ldquo;<U>Plan Shares</U>&rdquo;) to employees, directors and consultants pursuant to the Company&rsquo;s equity incentive
plans, pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently
filed periodic report under the Exchange Act and as provided in the SEC Reports. Except as set forth in the SEC Reports, and except
for the Plan Shares and stock options granted to employees, directors and consultants pursuant to the Company&rsquo;s equity incentive
plans, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any
right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common
Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There
are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion,
exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There
are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom
stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company
are duly authorized, validly issued, fully paid and nonassessable, have been issued in material compliance with all federal and
state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights
to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Securities. Except as disclosed on Schedule 3g, there are no stockholders agreements,
voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party
or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial
statements included within the SEC Reports (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise)
that are material to the Company other than (A) trade payables and accrued expenses incurred in the ordinary course of business
consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant
to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending
before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated
by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably
expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties,
operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws
at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the
date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Liti</U>g<U>ation</U>. Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation,
proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) which adversely affects or
challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any
Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current
or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of
the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s
or its Subsidiaries&rsquo; employees is a member of a union that relates to such employee&rsquo;s relationship with the Company
or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the
Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company,
no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other
contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive
officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters.
The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating
to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be
in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance</U>. Except as disclosed in the SEC Reports neither the Company nor any Subsidiary: (i) is in default under
or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result
in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it
is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument
to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived),
(ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or
has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product
quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater,
land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such
permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued
by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as
described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a
Material Adverse Effect (&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice
of proceedings relating to the revocation or modification of any Material Permit.</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company
and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of
such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the
Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor
in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities
held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which
the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in
the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual
Property Rights</U>&rdquo;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise)
that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate
or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since
the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise
has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not
have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all
of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries
are engaged, including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors
of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary
is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and
directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise
requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which
any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member
or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements
under any stock option plan of the Company.</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Sarbanes-Oxley; Internal Accounting Controls</U>. Except as disclosed in the SEC Reports, the Company and the Subsidiaries
are in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of
the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective
as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general or
specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed
such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures
of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange
Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under
the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control
over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers
shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees
of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for
the Securities, will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company
Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo;
subject to registration under the Investment Company Act of 1940, as amended.</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Registration Rights</U>. Except as provided in this Agreement, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the
listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the
foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company and the Company is current in payment of the fees to the
Depository Trust Company in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if
any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Company&rsquo;s articles of incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result
of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including
without limitation as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or
their agents or counsel with any information that it believes constitutes or might constitute material, non-public information
which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely
on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or
on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions
contemplated hereby is true and correct and does not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not
misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken
as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made,
not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Inte</U>g<U>rated Offerin</U>g. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set
forth in Section 3.2, neither the Company, nor, to the Company&rsquo;s knowledge, any of its Affiliates, nor any Person acting
on its or, to the Company&rsquo;s knowledge, their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated
with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the Common
Warrants or Common Warrant Shares under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect
to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. The SEC Reports set forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred
in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal,
state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction
to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown
or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate
for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company or of any Subsidiary know of no basis for any such claim.</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Forei</U>g<U>n Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or
any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used
any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political
activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic
political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any
Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated
in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Accountants</U>. The Company&rsquo;s accounting firm is Farber Hass Hurley LLP. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion
with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending March
31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each
of the Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents
and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor
or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated
thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction
Documents and the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities.
The Company further represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company
and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the
contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that:
(i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or
selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the
Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser,
specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing
of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded
securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a
party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser
shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Securities are outstanding, and (z) such hedging activities (if any) could reduce
the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities
are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of
the Transaction Documents.</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid
to the Company&rsquo;s placement agent in connection with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>[RESERVED].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted
(i) in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the
fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law.
No stock option granted under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted,
and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly
coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company
or its Subsidiaries or their financial results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge,
any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve
System (the &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls,
directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
&ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to
the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, no registration under the Securities Act is required for the offer and sale of the Common Warrants or the Common Warrant
Shares by the Company to the Purchasers as contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold
any of the Common Warrant or Common Warrant Shares by any form of general solicitation or general advertising. The Company has
offered the Common Warrants and Common Warrant Shares for sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo;
within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Disqualification Events</U>. With respect to the Common Warrant and Common Warrant Shares to be offered and sold
hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer,
any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of
20% or more of the Company&rsquo;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale
(each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person
is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer
Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection
with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(pp)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notice of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date
of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time,
reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby
represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date
therein, in which case they shall be accurate as of such date):</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate,
partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of
the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have
been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the
part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered
by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser,
enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Understandin</U>g<U>s or Arran</U>g<U>ements</U>. Such Purchaser is acquiring the Securities as principal for its own
account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of such Securities (this representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant
to the Registration Statement or Resale Registration Statement or otherwise in compliance with applicable federal and state securities
laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. Such Purchaser understands
that the Common Warrants and the Common Warrant Shares are &ldquo;restricted securities&rdquo; and have not been registered under
the Securities Act or any applicable state securities law and is acquiring such Securities as principal for his, her or its own
account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities
Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the
Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state
securities law (this representation and warranty not limiting such Purchaser&rsquo;s right to sell such Securities pursuant to
a registration statement or otherwise in compliance with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is,
and on each date on which it exercises any Common Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined
in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &ldquo;qualified
institutional buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the
prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able
to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such
investment.</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents
(including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the
Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.
Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided
such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.
Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities
and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser
agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement
Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such
Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly
executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the
time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company
setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof.
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation
set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment
decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such
Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors,
employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection
with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance
of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating
or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article,
notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general
advertisement.</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt,
nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
IV</B></FONT><FONT STYLE="font-size: 10pt"><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Removal of Legends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Common Warrants and Common Warrant Shares may only be disposed of in compliance with state and federal securities laws.
In connection with any transfer of Common Warrants or Common Warrant Shares other than pursuant to an effective registration statement
or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b),
the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and
reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company,
to the effect that such transfer does not require registration of such transferred Common Warrant under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Common Warrants
or Common Warrant Shares in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a)
UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a
registered broker-dealer or grant a security interest in some or all of the Common Warrants or Common Warrant Shares to a financial
institution that is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) under the Securities Act and, if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured Common Warrants or Common Warrant Shares to the
pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of
legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be
required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of Common Warrants and Common Warrant Shares may reasonably request in connection with a pledge
or transfer of the Common Warrants or Common Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The certificates evidencing the Common Warrant Shares shall not contain any legend (including the legend set forth in Section
4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act,
or (ii) following any sale of such Common Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Common Warrants),
or (iii) if such Common Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants),
or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the
Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder, or if
requested by a Purchaser, respectively. If all or any portion of a Common Warrant is exercised at a time when there is an effective
registration statement to cover the resale of the Common Warrant Shares, or if such Common Warrant Shares may be sold under Rule
144 (assuming cashless exercise of the Common Warrants) or if such legend is not otherwise required under applicable requirements
of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such
Common Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer
required under this Section 4.1(c), the Company will, no later than the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company
or the Transfer Agent of a certificate representing Common Warrant Shares, as applicable, issued with a restrictive legend (such
date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing
such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give
instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Common Warrant Shares
subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the
Purchaser&rsquo;s prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Common
Warrant Shares issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser such liquidated damages
and other amounts as described in the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Shares, Pre-Funded Warrants and the Pre-Funded Warrant Shares shall be issued free of legends.</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Furnishing of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Until the later of the time that (i) no Purchaser owns Securities or (ii) the Common Warrants have expired, the Company
covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time
that all of the Common Warrant Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in
compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company shall fail
for any reason to satisfy the current public information requirement under Rule 144(c), and the Company shall fail to satisfy
any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s
other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by
reason of any such delay in or reduction of its ability to sell the Common Warrant Shares, an amount in cash equal to one percent
(1.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Common Warrants on the day of a Public Information Failure and
on every thirtieth (30th) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date
such Public Information Failure is cured and (b) such time that such public information is no longer required for the Purchasers
to transfer the Common Warrant Shares pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this
Section 4.2(b) are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo; Public Information Failure
Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments
are incurred and (ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments
is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information
Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein
shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public Information Failure, and such Purchaser shall
have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect
of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities
in a manner that would require the registration under the Securities Act of the sale of the Common Warrants or Common Warrant
Shares or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading
Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval
is obtained before the closing of such subsequent transaction.</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing
the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction
Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of
such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information
delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors,
employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon
the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers,
directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other
hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or
without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide
the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall
not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any
regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities
law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is
required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such
disclosure permitted under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any
other Person, that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination,
poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue
of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated
by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither
it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes,
or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have
consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.
To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or
Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby
covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or
any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public
information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital
purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment
of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common
Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold
each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each
Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act),
and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a &ldquo;<U>Purchaser Part</U>y&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages,
costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and
costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of
the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents
or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by
any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated
by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with
any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct) or (c) in connection
with any registration statement of the Company providing for the resale by the Purchasers of the Common Warrant Shares issued
and issuable upon exercise of the Common Warrants, the Company will indemnify each Purchaser Party, to the fullest extent permitted
by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable
attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged untrue statement of
a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement
thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto,
in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that
such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the
Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action
shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser
Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel
of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (x) the employment thereof has been specifically authorized by the Company in
writing, (y) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (z) in such
action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company
and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses
of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for
any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably
withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any
Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party
in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred.
The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party
against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue Shares, Common Warrant Shares and Pre-Funded Warrant Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.10<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Listing of Common Stock</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall
apply to list or quote all of the Shares, the Pre-Funded Warrant Shares and Common Warrant Shares on such Trading Market and promptly
secure the listing of all of the Shares, Pre-Funded Warrant Shares and Common Warrant Shares on such Trading Market. The Company
further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such
application all of the Shares, Pre-Funded Warrant Shares and Common Warrant Shares, and will take such other action as is necessary
to cause all of the Shares, Pre-Funded Warrant Shares and Common Warrant Shares to be listed or quoted on such other Trading Market
as promptly as possible. Until the later of the time that (i) no Purchaser owns Securities or (ii) the Common Warrants have expired,
the Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading
Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules
of the Trading Market. Until the later of the time that (i) no Purchaser owns Securities or (ii) the Common Warrants have expired,
the Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company
or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust
Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.11<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary, shall issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From the date hereof until six (6) months after the closing date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means
a transaction in which the Company issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable
for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange
rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at
any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that
is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence
of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock.
Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall
be in addition to any right to collect damages. Notwithstanding the foregoing, the Company shall not be prohibited from entering
into, or effecting a transaction under, an at-the-market offering agreement whereby the Company may issue securities at a future
determined price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable
Rate Transaction shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.12<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be
offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless
the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision
constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended
for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or
as a group with respect to the purchase, disposition or voting of Securities or otherwise.</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.13<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or
sales, including Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this
Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the
initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms
of this transaction. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the
Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it
will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by
this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser
shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable
securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant
to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty
not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release
as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle
whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have
no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s
assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that
made the investment decision to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.14<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>[Reserved]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.15<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Common Warrants and Pre-Funded Warrants set
forth the totality of the procedures required of the Purchasers in order to exercise the Common Warrants and Pre-Funded Warrants.
No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Common Warrants
or Pre-Funded Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise
the Common Warrants or the Pre-Funded Warrants. The Company shall honor exercises of the Common Warrants and Pre-Funded Warrants
and shall deliver Common Warrant Shares and Pre-Funded Warrant Shares, as applicable, in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.16<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Form D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Common Warrant and Common
Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company
shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify
the Common Warrant and Common Warrant Shares for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue
Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.17<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Resale Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company shall file the Resale Registration Statement on or before June 6, 2022 and use its best efforts to cause the
Resale Registration Statement to become effective as soon as practicable thereafter. For the avoidance of doubt, the Resale Registration
Statement shall only be filed on Form S-1. In the event that the Company files a registration statement on Form S-1 with respect
to any of it securities with the Commission prior to June 6, 2022, the Common Warrant Shares shall be registered pursuant to such
registration statement and, in such case, such registration statement shall fulfill the obligations of the Company with regard
to the filing of the Resale Registration Statement. The Company shall bear all expenses in connection with the filing of the Resale
Registration Statement. The Company shall use its best efforts to maintain the effectiveness of the Resale Registration Statement
for a period of at least one (1) year following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reporting Requirements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT><FONT STYLE="font-size: 10pt">i.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>With a view to making available the benefits of certain rules and regulations of the Commission that may at any time permit
the sale of the Common Warrant Shares to the public without registration or pursuant to a registration statement, the Company
agrees to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">A.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>make and keep public information available, as those terms are understood and defined in Rule 144;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">B.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>file with the Commission in a timely manner all reports and other documents required of the Company under the Securities
Act and the Exchange Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">C.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>so long as the Purchaser owns Common Warrant Shares, furnish to the Purchaser upon request (A) a written statement by the
Company as to whether it is in compliance with the reporting requirements of Rule 144, the Securities Act and the Exchange Act,
or whether it is qualified as a registrant whose securities may be resold pursuant to Commission Form S-1, (B) a copy of the most
recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (C) such other
information as may be reasonably requested to permit the Purchaser to sell such securities pursuant to Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Blue Sky</U>. The Company shall obtain and maintain all necessary blue sky law permits and qualifications, or secured
exemptions therefrom, required by any state for the offer and sale of Common Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-transform: uppercase; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ARTICLE
V</B></FONT><FONT STYLE="font-size: 10pt"><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder
only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the
other parties, if the Closing has not been consummated on or before the fifth (5th) Trading Day following the date hereof; <U>provided</U>,
<U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall
pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by
such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall
pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter
delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection
with the delivery of any Securities to the Purchasers. The Company hereby agrees to pay, or reimburse if paid by the Placement
Agent, the Placement Agent for certain expenses as set forth in that certain Engagement Letter Agreement, dated April 29, 2022,
by and between the Company and the Placement Agent (the &ldquo;<U>Engagement Letter</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and
the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof
and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge
have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after
the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment
at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30
p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be
given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a
written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest
of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or,
in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment,
modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately
impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise
any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations
of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in
accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not
be deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any
Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound,
with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties
of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.9<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Placement Agent and Fees</U>. The Company and the Purchasers hereby acknowledge and agree that (a)&nbsp;the Placement
Agent is acting solely as a placement agent in connection with the execution, delivery and performance of the Transaction Documents
and is not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for such Purchaser,
the Company or any other person or entity in connection with the execution, delivery and performance of the Transaction Documents,
(b)&nbsp;the Placement Agent has not made and will not make any representation or warranty, whether express or implied, of any
kind or character, and has not provided any advice or recommendation in connection with the execution, delivery and performance
of the Transaction Documents, (c)&nbsp;the Placement Agent will not have any responsibility with respect to (i)&nbsp;any representations,
warranties or agreements made by any person or entity under or in connection with the execution, delivery and performance of the
Transaction Documents, or the execution, legality, validity or enforceability (with respect to any person) thereof, or (ii)&nbsp;the
business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company, and
(d)&nbsp;the Placement Agent will not have any liability or obligation (including without limitation, for or with respect to any
losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by
the Purchasers, the Company or any other person or entity), whether in contract, tort or otherwise, to the Purchasers, or to any
person claiming through it, in respect of the execution, delivery and performance of the Transaction Documents. The Company shall
be responsible for the payment of any placement agent&rsquo;s fees, financial advisory fees or broker&rsquo;s commissions (other
than for Persons engaged by any Purchaser) relating to or arising out of the transactions contemplated hereby, including, without
limitation, any fees, expenses or commissions payable to the Placement Agent pursuant to the Engagement Letter.</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents)
shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not
to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that
such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party
shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.12<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and
effect as if such facsimile or &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.13<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions
set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties
hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially
the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to
be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without
including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.14<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any
similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option
under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided,
then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any
relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>,
that in the case of a rescission of an exercise of a Common Warrant or a Pre-Funded Warrant, the applicable Purchaser shall be
required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such
Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&rsquo;s right
to acquire such shares pursuant to such Purchaser&rsquo;s Common Warrant or Pre-Funded Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.15<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in
the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance
of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.16<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery
of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The
parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations
contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any
such obligation the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.17<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered
from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other
Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of
action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.18<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way
for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained
herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed
to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated
by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without
limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary
for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented
by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience
only, each Purchaser and its respective counsel have chosen to communicate with the Company through Mintz. Mintz does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same
terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any
of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.19<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing
under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated
damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial
liquidated damages or other amounts are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.20<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised
on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.21<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity
to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to
be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be
subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.22<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>MODULAR MEDICAL, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Address for Notice</U>:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">E-Mail:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Fax:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">With a copy to (which shall
not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO MODD SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Purchaser:</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Signature
    of Authorized Signatory of Purchaser</I>:</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email
    Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 70%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address for Notice to Purchaser:</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Address for Delivery of Common
Warrants and, if applicable, the Pre-Funded Warrants, to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Subscription Amount: $ _____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Shares: _____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Purchase Price per Share and
Accompanying Common Warrant: $_______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Pre-Funded Warrant Shares:
_____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Purchase Price per Pre-Funded
Warrant and Accompanying Common Warrant: $__________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Common Warrant Shares: _____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Beneficial
Ownership Blocker <FONT STYLE="font-family: Wingdings">o</font> 4.99% or  <FONT STYLE="font-family: Wingdings">x</font>
9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">EIN Number: __________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Schedule
3(g)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">Mr. <FONT STYLE="background-color: white">Paul
DiPerna, Chairman of our Board&nbsp;</FONT>holds voting power over 333,000 shares held by his adult daughters</FONT></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Modular Medical Announces $8 Million Registered Direct Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>SAN
DIEGO, CA / ACCESSWIRE / May 3, 2022 /&nbsp;</B>Modular Medical, Inc. (the &ldquo;Company&rdquo; or &ldquo;Modular Medical&rdquo;)
(NASDAQ:MODD), today announced that it has entered into a securities purchase agreement with institutional investor Sio Capital
Management (the &ldquo;Investor&rdquo;) in connection with a registered direct offering of an aggregate of 449,438 shares of its
common stock at an offering price of $4.45 per share, and, in lieu of common stock, pre-funded warrants to purchase up to 1,348,314
shares of common stock at an offering price of $4.44 per pre-funded warrant, which represents the per share offering price for
the common stock less the $0.01 per share exercise price for each pre-funded warrant. Concurrent with the registered direct offering,
the Company has also agreed to issue to the Investor unregistered common stock purchase warrants (the &ldquo;Private Placement
Warrants&rdquo;) to purchase up to 1,438,202 shares of common stock in a private placement. The Private Placement Warrants have
an exercise price of $6.60 per share and are exercisable beginning six months from the date of issuance for a period of five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Oppenheimer &amp; Co. Inc. is acting as the sole placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">The
gross proceeds from the registered direct offering and concurrent private placement are expected to be $8 million before deducting
placement agent fees and other estimated offering expenses. Modular Medical intends to use the net proceeds from this offering
for the Company&rsquo;s operations, including the development of its products, and working capital and general corporate purposes. The
registered direct offering and concurrent private placement are expected to close on or about May 5, 2022, subject to the satisfaction
of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">The common stock
and pre-funded warrants and shares underlying the pre-funded warrants described above (but not the Private Placement Warrants
or the shares of common stock underlying the Private Placement Warrants) are being offered pursuant to a &ldquo;shelf&rdquo; registration
statement (File No. 333-264193) that was filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) on April 8,
2022, as amended on April 15, 2022, and declared effective on April 19, 2022. Such shares of common stock may be offered only
by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus
supplement and the accompanying prospectus relating to the offering of the shares of common stock, pre-funded warrants and shares
underlying the pre-funded warrants will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying
prospectus relating to the offering of common stock, pre-funded warrants and shares underlying the pre-funded warrants may be
obtained, when available, on the SEC&rsquo;s website at&nbsp;<U>http://www.sec.gov</U>&nbsp;or by contacting Oppenheimer &amp; Co.,
Inc., Attention: Syndicate Prospectus Department, at 85 Broad Street, 26th floor, New York, NY 10004, or via email at&nbsp;<U>equityprospectus@opco.com</U>&nbsp;or
telephone at (212) 667-8055.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">The
Private Placement Warrants issued in the concurrent private placement and shares of common stock underlying the Private Placement
Warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;),
and Regulation D promulgated thereunder and, have not been registered under the Act, or applicable state securities laws. Accordingly,
the Private Placement Warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant
to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable
state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">This
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor are there any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>About
Modular Medical</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Modular
Medical, Inc. (NASDAQ:MODD) intends to launch the first next generation of insulin delivery technology that will be both affordable
and simple enough to learn and use to transform the insulin pump market into a mass market. Our patented technologies will eliminate
the tradeoff between complexity and efficacy and seek to set new standards for insulin dosing that most closely mimics nature.
Our mission is to improve access to the highest standards of glycemic control for people with diabetes taking it beyond &ldquo;superusers&rdquo;
and providing &ldquo;diabetes care for the rest of us.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Modular
Medical was founded by Paul DiPerna, a seasoned medical device professional and renowned microfluidics engineer. Prior to founding
MODD, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes (TNDM) and invented and designed its t:slim insulin pump.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">This
press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause
actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, market
and other conditions, statements with respect to the completion of the registered direct offering and concurrent private placement,
the satisfaction of customary closing conditions related to the registered direct offering and concurrent private placement and
the intended use of net proceeds from the registered direct offering and concurrent private placement, whether the Company can
successfully develop the Company&rsquo;s proprietary technologies and whether the market will accept the Company&rsquo;s products and services,
and the impact of COVID-19, general economic, industry or political conditions in the United States or internationally as well
as other risk factors and business considerations described in the Company&rsquo;s SEC filings, including the annual report on Form
10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. In addition,
any forward-looking statements included in this press release represent the Company&rsquo;s views only as of the date of its publication
and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to update
these forward-looking statements, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt">All trademarks mentioned herein are the property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>CONTACT:</B><BR>
Jeb Besser<BR>
Chief Executive Officer<BR>
Modular Medical, Inc.<BR>
+1 (617) 399-1741<BR>
<U>IR@modular-medical.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>SOURCE:&nbsp;</B>Modular Medical, Inc.</FONT></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>modd-20220502.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /685w7xRiXgOn8uAbHZMSaaBucOdzpR0ielBvGZxHbkajyAlt++RNSBLyglWAagK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:MODD="http://modular-medical.com/20220502" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20220502">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>modd-20220502_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>modd-20220502_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20220502.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>modular001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!% +, P$1  (1 0,1 ?_$ *$  0 !!0$!
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M\82#Z?A-8F$^+6_V+'\CY4X',(/B-S<[FZPB[>&C7ZK":KOSF"V[$\=M^?\
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M36JP.ST%:H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M\15K;?\ %WC[71 ^\-B;-IH^CQ]9:5]2VL;(XHV,:&AC&-#1T  Z!8%P@("
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M\7YM1M>14QZ^FNBEB*.?VN^*Z'[4@EB'R-\D%60?5(ZE85* @(" @(" @("
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MZNE4$H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""F6$GI0=?G0>!$X=
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MP=E-!?F0$5DDVL8QATK]4N^19'2D$H" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @  (" @("
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M$H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @\.E#>ORT]004A>1]:M
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0S*.\C9MZ?;VT_K09!!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140098872983176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16772 W. Bernardo Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>modular_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="modd-20220502.xsd" xlink:type="simple"/>
    <context id="From2022-05-02to2022-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-05-02to2022-05-02">0001074871</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-05-02to2022-05-02">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-05-02to2022-05-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-05-02to2022-05-02">2022-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-05-02to2022-05-02">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-05-02to2022-05-02">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-05-02to2022-05-02">001-41277</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-05-02to2022-05-02">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-05-02to2022-05-02">16772 W. Bernardo Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-05-02to2022-05-02">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-05-02to2022-05-02">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-05-02to2022-05-02">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-05-02to2022-05-02">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-05-02to2022-05-02">800-3500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-05-02to2022-05-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-05-02to2022-05-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-05-02to2022-05-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-05-02to2022-05-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-05-02to2022-05-02">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-05-02to2022-05-02">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-05-02to2022-05-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-05-02to2022-05-02">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-05-02to2022-05-02">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
M8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSA
MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB
M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>
M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&
M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%
M=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#5
M2?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7
M>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;
MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y
MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH
MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \
M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH
M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z
M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^
M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (  ^(I50'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #XBE
M5)TI>,[N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ #XBE5)E<G",0!@  G"<  !,              ( !
MS $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  /B*54Z.4Q_U,$
M  #&$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ #XBE5)^@&_"Q @  X@P   T              ( !
ME@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  /B*54EXJ[',     3 @
M"P              @ %R#P  7W)E;',O+G)E;'-02P$"% ,4    "  /B*54
MJL0B%C,!   B @  #P              @ %;$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ #XBE5"0>FZ*M    ^ $  !H              ( !NQ$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #XBE5&60
M>9(9 0  SP,  !,              ( !H!(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  ZA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="modular_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="modular_8k.htm">modular_8k.htm</File>
    <File>ex10_1.htm</File>
    <File>ex4_1.htm</File>
    <File>ex4_2.htm</File>
    <File>ex5_1.htm</File>
    <File>ex99_1.htm</File>
    <File>modd-20220502.xsd</File>
    <File>modd-20220502_lab.xml</File>
    <File>modd-20220502_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "modular_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "modular_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20220502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20220502_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20220502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MODD",
   "nsuri": "http://modular-medical.com/20220502",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_8k.htm",
      "contextRef": "From2022-05-02to2022-05-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://modular-medical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_8k.htm",
      "contextRef": "From2022-05-02to2022-05-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001019056-22-000371-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019056-22-000371-xbrl.zip
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M#[=-#ZN<?^1_=68^_/0:A2S?*2BS]T!]@&W*MTQX :DXSLLVO\$]&SL@>#A
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M&RJ-4O!DHDG8>2/)LEFW'OL@J![R;5.)*_?3AZ#H;()'D5)X5",9H+F<HW$
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M&5S<*U>Y7%&FX*[="^,AGDK!30\^SGJ#M+:>IWJT]'T?+:U+$M4F69-_"8$
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ME 9CE(^1Y(FCOK"$Y$X_G#=%F>Q_GR8'3P\.DIU0U!WKLX2IMF(N3;S)%%Z
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M@X@=@[]([\08EXIWBV]7VIJ>A.YN"OHN&WM7/?3/\&F'8O%^#+6^:"1%1X#
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M;?SZ(6/"7C\@05JJ'(5D(IZ>NNVQ0?(&TQ/!!U*B_#EOIGF#R(;5O(YJ-ON
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M^G""<*0H+9@;%)/@BD!T]"=N-V:M#%._..'D.C<Q?;C&M5[\@.TE*8N/R)1
M-TH//9!&AY.L',T=^K?)WN9VDW3>(S@.>+N_N8NO:@7Y+6S-45-_9#=E36L&
M1]+S8N6YKY?!&'+6=Q%6(05$A>SK]CPCN6'Y?:G9'MGDNFC9T>$+AJ32%\(L
MCZ4,'U*4I7C%(\L"QX"RBEK#_WJ?D82#8E1$@29F"1QT %$*#Q9VOBP#W*O(
M%<+'"*L1N H@4:U"YS'V'44'A2EHQ 6XK?/!#H@=&]B8L-MV8-Z&@Z#EAN.K
M5-%TV,7-/%FLBIQ_[JQLKK>Y^_HG=1@=<KM6#LFJ@O*L* O?2%9Y#[5#!12S
M63[!3T@2=U3N>YP7<[(7U45&2";2*4S5&AL&D3#\\ 6J 9B#-E;UB(L]&/UK
MEF>5D>W#8;*2 5_O?__\*?,]SXAL-1P[GRB%)@?1#S(%I:YY6\=".E@8XRX=
M1X78P;$"8A.O' U'D*P:P'V\<R\>O7/W\\Z]>/3.?;;\6VQ&M"VHZNFQ3E95
M"<N7#2@-Y2IW\5VMAS6F1)I;0EYHU'J4ZXKCWB.IU\P>0]9U2VAMDS76Z\W8
M!V\-ZO17=$OEG&Y\9IR@P6UHZ[G+PI&U&RV'<; S<J9/4%O PZDMR2A[?QQ#
MGW.6:)$W@3PP.:J/L!6ML808&^3,3@;2"<!-V;3L?@N(\-W85GA#8IGX@]04
MEV7B@&.69\QJ<4R783I']J3MW; PBF"*J-W] U^&=D4UD73 "^ "FD)?B<D\
M"*%'[3; E 0K71LBN1+7G%"&<'$+*,W,N!VVT9UB67P=0KU*V8*4[.UW8-\-
M3W.CE)O<Y;Z*QBH8S])= "<\C11_SMM<ROXM.G5*$-C#T^#$4A 9X&/.T*H1
MQ,^/$,L1<:M62::X)R+.FKHJQFP 3&DS-O7BDE?G=4Z,_9A*=H%AW8&SRDR]
MO -'8$*T%*+/<ZUXOKVULLF(8<+QZ&$?-UG>WFR&O#WTF&Y<A@N0>.23.77)
MZFO2:B+5O@P4$O>CCU@HR6DQ)71!&M1$X<@[?&3+B"C>HY9*CUS(D@M#I%[E
MAV,P(GF%G\[K @_9'$_43H@=L;G<+K#N@.6J2NQZWX K!P8G[TFG$^/+(*XN
M;)LU(-E*X;1V58D*JM_HVB464:JGY$H8[2H1 --53H5T6\#'84N:+T2^$$[[
M9=/&SZ"(0>^,((/$L4[(J;-?]T[K=%&"N5>*&"_"^J6U*U?JOY?9]#,3]088
MY ,'HT)"$-O+%>QNZ^BO714G-RZE?<.$JX;(V@:_VF 'Q:>O[Z#PXN*U<Y,'
MVGG,?Q:0LL72XN_K3H([P>\@NTT)/HWOH#.A>1!%YUGUK*\O8WKCFJ,/XC^[
MLO:%08:;PR$^DJ)A[Z*>O*K-2Q^^M]$PO=[ENN>B-5V!=#I<J),L%/]AXJO"
M(,,<<WW;%N&PN PRK#JK:+$A,"'JQ UEN"\YZM;&3&)O[*2A-#GJ!9)!X*G>
M^F3B6IR)I()=7@2\KK*5@O*>)A8CJ#W>#[@"*_%60V&'</;&Z:#K(@FIBJ]X
M4I (%#L8#MJZS8JZ[8BT&ZHMQO/9-+F4,G/<>[9^;+\.&:> 1,N0F1IDANT0
M]$1\YLY5QDSJXA>I-+:]U2\UAANA];PPL(YMKCE /:^_*8;5W>0EQIA66@Z#
MA!Y6, A1DD'_:J2^KK_0!-^GR!L%K.\^_U]DZCW"G!8"63:'-=_<9A\[JU10
M#CB%*BAK?UJHO\ZJ<O4[PK,M_#Q40KV0%%!$JMXQ;"*')*A@7?L29F.*%@;Q
M*+7;G^T=B/EX+S_J-X]^U/OY4;]Y]*-^MIJVW Q[#E82(8U:F8*+H;Y'J%)!
MY0TNL;)GNYBI@,V073(;1Q0>U9K[,H Y4)T0@ -+#HO!B4UC&:E$'NE Z7VM
MW@FK5'4PO*E]VH6O,Q#H<J05%"&#]9JF^:[WBI^"TC4=3O]*O1RL<0*YK'8F
M=IUQ_0K7,TB#,64NF5_@K;%8!@]+M?>>P#>E9]1AC<8=+]QEQ,SA^PB=.Y<-
M5_KALE=4]T5_U_:O773FS!<-LB[0**0J6=^US1>/<H72#3ATC =^RNVMWWA/
MT"R)7TD^2LZYPM,J3WKJJES0G64*Z>#O.#/ \V0Y ]PMPTK'H5'D5WOIT;/@
M/8CLXL4)W63GT;\VR28\QQ*FU5B"U*\,2"HLTQFKN-1?BR@0.)7(]65!!3'8
MO*"8#>])CF?W826"@6-")I,C'J\QGSCL<NH.!=8NI<=I,[J$W(AX0564(*:8
MFH)O(]%*J91RL@4#TU,GYUE!<\5IN*I)K?!Y.#CK)!\%%<9-43O,7'%>+Y1Y
M56)J]ID'=Z50-9D3Q'O8+P?HO5D\-*]AJ[VZJ SVJYU1HK*6;Z/ 6X-)-U48
MH<^8UEVB]P+79.O;<L'X[_UX;'FXBJ<Y^\BIF B187 P QGFY();4'*E_"(&
MHS=.1'U=N(W2< L+(O!WSGV/M<R!)/TFN\Z*4N'*G87=^WI_Z@]W96<'&5K#
MHN5N5]L=3^(:]7&*KZ1L,K!M4Q;00[*E,C:SBT[750]79"HY)P!VS[B8T_ 7
MK1>?V-W4%TOSL'HZF/-LR;^6=.+8'F=&1U^/T:?-NB3D)GIB5A3?HT 'IZE3
M>I:<DU&^K,7F=RO!'122YA&G.YO#D.S$9H.LFV*FD14W-*F:J/U;,KI\U8CQ
M?;NQ,%J8HD>7=386-U.@*O#=AO:>K&XLG@0Z62'!&]ATS656";:>T@]E.X1>
M;$3&-8MYI^6V@E^I1SHC3NJF:">%#\"@X5OE1,;AY.SVUC"7PS*I>$-O15X(
M;M1%1QXJ"D6BJ)8CB$XW_NNDPOG,)U&&K$'\/17ZPTBN>IP,A.",4HXY>:.D
M4D9_ZN,0+(V+[YE!0V]O(0JJ378^L;9C#P#VC)-&L0(@Y85BMW2?W;!_SV0_
MON#D1YMDR\P[LF5;A[G4?$7*_\9!K*FEBHRCRUU:@,M%)GH^<KY.:LF%M)>/
M+0EKH@.]C6\F@P(/]%L$F86TZ7P_8Q2#H:/ME6<TO:4R:R"G1UE)T8'V*H=M
MME.;ZN=T/V#Y\UW'F>%'B=+?C!.[7N67=5?()"IQ/*_5A$.4[ AF0A\^7QHY
MZKL_Z5BLF7GAF?W7K@AYKIGNF4!POQ#!E\L)CNX'A&\:.K#6RE J%2S7$V5+
MK" PNS-G3DCA'\.MVI.PP7&6+/LZ2K5A',@^)>?(MQ]"GZ:U8YVW9N(=R5S6
M\_?0;7FG:M&W^= Y17N'^)M].5-.YZ!:+A79QC@^%'7"QB<EM!-/\X]1SEGN
M4A*5K-9\/,7LO"N,>W0P87"4%TU%+.6>HHOK'F=:"49VOQ2AM-?7H *$@#Y3
MI:)N64<G>F=D"C22+RQV0"RV7C@*>7HRK(N-TTPB/47Q=L-.Y$G.L!N?.X5'
MOE( SFU#]!KEE6#ZLQ;3&E7YKNN/K8E<F[T Z_3/!5%M13@3<=0^C$?#GS(1
M J=0P?+G3%\HMIA^XR8UWG\:L.T^F/Q+KA74L.P'=6A1T<SS:\6E[SHCMA5!
MXH,Y$_4=?D5ZFB]Z,51=?$$E31**,6_(#XW$0SV-;@9X*4PSSXFC1: NW<M-
M_>VCF_I^;NIO']W4GWW+C4;_[EO.WV]O4):K9[J"0]:@N9&<:@DN*4]X)[V#
M7<&WD)M0Q+C_.[K +@/FF'D?&1 /,4<Z@>(6[[Q5'F2PF"?<A>D"(^W$2UF!
M,35=2!*<())@EB^+*9&EXS'!(&;(;N-^Y3A(N#XA"3^])5&PPC4)FV.,M4?
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M].!@DW?I9/+U[KI#A[P@L7GFL$C# *M^@OO,!R0BJ-MU8 ZTOF*03MR1+-E
M#<Q+Q[TPSN;9V"G&H'//W%; PO882738D-A6BP([?1;%:A1(QS"0<&C314.7
M7##$(4C%#X:0/X/$8"Z([JJY]Z[O';:/25-7XD69A=V[CS$*!PN&*!ZFT=+S
MZTR(*?L2.0?TVO&C4I"B4KP:%)J-O5_SK2G@PQ7IN7&XY.U]UF6A"@1YPQME
M3)RTOA3!<.O.S=8-XVF]RJ^ZP&Y S"."+@,_$?U$#;<CP5CDJY&X1SJF":_[
MH#!GS754?#>^>BYIA,D<Y%#4RK8PR;'*/;;FV1UNQZK*W(6Z!Q\&E-F]5=Q@
M'UB>?_U[_3:YZ7:%YMX<BG;+$O.P6G97'+OI;Q!*9&ESIDAF+)Y+-V%FR88R
MIO TN;C#CJF3(>B6%N$M.U,FW7F^M_],8A9(5TE.),'6:DD0(]4&.$CBF,*H
M[6Y UVDDN-NQ6?LQ\ON:KP%?E344+O0EDX4BM*'M6-F6@\MI3J#0Y(3RQR)1
M'-WZ&SO?L;+H2N0$:;@2\(#Q%M>TO37OV_S,\::8S[APE8S&TVNS'8&0CWY\
MWCE9'&\/>LRD9-P\8[))29:JYP2/9#"(*_1ACV]?"*>>ETLJESA>XF&" FQY
MG)KDG+% :R;!OC--V-% 0IQ#KG@/<Y!,KF[.YY!1S*FUW-!:A,TA64.%7EXJ
M(Y 4,(.2ORI#AP;&JQ +HIJ6RR<4,4+^)S?7+Y7Q*Y@A034O4/X^43.NJ.XV
M>.\1=(ZR\%H'&Y&+G*^RI#TC+8Y;>,CEW;13];44DQ$DNL<G<8Z;(18+[QZE
MZ1"^@PE*#%-GNR(:&T*AN>N624@\BPUCB09JE)VQI>H?J^:,*F_HI,55I#YN
M?Z@R8?".1 D6&6L"68)3Q]S;V),K^!$I4RQ F:,0XTU-@74J.Y+W!J@M?%+N
MFK9)-[BO?;0V=8$L6NKABV -R*^Z*\E+8 DMM-A" +1QH!?#$NO4#[2ANJ6C
MFVU[QDV2L5+@3QLQ@+G^1\??(!>34 8R)&2-%DY-L36(1WO&54Y((QB,>(B?
MR1)T0,*/734"GH"[4:BL<RE_]^A2OI]+^;L'YE+>+$-[.MT,\/.9+TC^*QU8
M3H\>FM(N<5T(,,/\?:1IJO*5B6("$,04%']=D>EI[RN6%7W:  'WUDU8P;+C
M1!%$@GB4#DQ6,3<%UAD3H,5B#*+8"0ZC%$I],-0?/.B1;$N!/QJ,I&7]8;<3
MB%E05PJB/4R=E4>4;ZD$1,G[.D-7M.2F33T&FFC+Y4>M, 5%WU9K*7H&0JJZ
MJ@ M<2DKV+OWRB1\(]I;HNG5WC#UZ7_K]%B'GTF]?X2M6J[#VPYJ\ 8=P=X[
M/.I T0I9R599[OZQ/STY]4L>_<O+K^1C^]]GQ^?'9W\_?OU_-GEZKJZ^G@N2
M61W>,V/\*=;S%E@)JAP!G?PEPI^&MN7J!/<A&?T-2%1IAJW9"*Z(-#!*!EYA
MDPR;=9YPR;#5E'.5A*!^(<:I0U70.:HP,;)HU KJX[8]X85X?0AU2$I<\'X'
M;46-K:#" &ZB>&8<A;))62BSF[WMK7=U?(+O,Z/&4S7^2+"VZ!U&]Q:(/S",
MY"V>S,:5Q5(:$F49=62L*#W)U)I+$!:GL-=B&G2NE103H<#Q2<CN5^A,89";
M7#[4"E&F!.W@DJ8"X6=8FP_(2MRDJL!Z\F+18&@LZ7 DS9>OXSY$B:,:1<@X
MBG=PRU/ 2=,;+6_A+&Q0ZL=[ LY0Q%+"OER)5RGT[Q/1OV-F&$?334D2K2S"
MG)^V^(FSV2.X@ B,T9'?V$*L^-B'O?,]T* J3?W.)K.BTA"?R,S;9D)[0&U=
M-%01;HF\.5G#!(*F4OG[-X=' 8'R!N_'WW_?I/U(LWN6VRI^OX NRT4=''?*
M*C9-S]:4HT.'G:Z\8F$!WBMIT_"Q<$!V2'2I"9'???^MY[T4$N0S> U2.AW5
M7/=X__OOOK&DD1Z@%C)?8CT_9KCFBHX#USB7#\J_7I6OO1=W$65??^?T]\\K
M) ?V.\91>MXNQR2[HW_=F))A'ERJ0LZ^S;O '8/HBV S)#OX$R\D7OUR=&B%
MA)JROER'BB;'TO0SP7CJQNE?;QB%"QN1REQO;YUS$8W>JWJ/]6K0_J%)J6^J
MUGA2L?;P*@?P% .B</[&)"U?_.>N<W#*:()L$<XX%3L7C#A&R%_7G<LE*12'
MU-U B\LGMGU2'VS;78UQ4/$W$H^$\DAC^U(^2RF9^LL,*[5Z=7J3ZR8TM.CO
M/J.J(&. 7&:UE(*H)3NUR%O-80*MS4'J#UG2,FDT/)=!\R7'=Q\WYO>/;LS[
MN3&_?V!NS$W29#Y^_-JQ[U\IY>MM1E8BG%FOIZ#>H10L=RC<0&1YU<14EC#I
MMIS6R<$=I+ 9T$AZ8]::26C*/_F8YW/-?_2U&F*9M4>D3(^Y@ZH2!R4US_3W
MAO7[VZ<]_<?WA?/A2C<Y!'%;:"W.6RM7=;XVU;#Z^O:6O^SZBP#_O G*KDNU
M]9IP!^RI/>5T7'R:B?DETLL>RT5#\C5,%[G$R4E]@@*7.J\GSC;)FE&!3 MT
M"U[7Y76?R&IHP\0P3-'A<.DF*4%)1A??-FMPU /D<W<%(J++J\TF2BC+KZ]D
M^@-^*A']4_7U"F3E2Q.R#!B4MK>8D&4EDWV/_Z,P %7%@A*G"+W,,BB$3!_J
M8NE]#(HEZV-#\$H/[))%D56;O,-FLW_?#@MH?GZ6*FKG' $QENTZE7Q @AA/
M=;C*A'R&65$P(*1%82/KNYKR17 VZ*W#GVKEM];TF62C?)YATF%'C*(#9R="
M9+A#L7V'^S+>A:FP]G")NLB60UB+5,AA[Z-<!G 2X6T%YQQCH8<:SZ#@-.+6
M/E9E2UX\W5]YLC9Y)U?5UXM5P'Y^7;3HP_=TY<?7GNS]M\C5UEONU3N $?"Z
M>TB"T7[V*@%EJXL2A/4'>!F_6<-89,%Z+HYH+#00T1,B!JR;-@T 1+B=$/S6
M#%R97%02S5#GU.0-*7_V#RF3G" WA\,[YIXRRA#:X,-<=IB4.>+!I:#QP=/_
M[%O1?<^KM:K%?!8SN#6!W'%6(MM*YZE_.#72V]SS^@:[HG((*XG6'9JY.YER
MC@[KEM%"/'_Z8N5"[&HLU=9]-$SAI($IU#US'!XT6A0*\'I$X-A2-LC=0.L#
M[7#A/):9@;,EM(*-8)1&7F43[%[=*"IMTMO=.,QVW!0CR0O2+;<SV=W9WR6
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MZH^P:R=Y5K)^S%4V,E\52LOBX47>(BL(JJ)EN4(16*WU4^<<@"+ CONXZ?U
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M\]Q;6EFSG__<EBL(E+/<GC&N@]5355_7UL7HZ7,>4OSFLF]$DL#^@N"%&GJ
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M>B]O3D9!7PG9+M5^+A$P2L'9O!B"RLBCNJ>YIU0<V:@UK[%=DM@\H2:'S5;
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M98JT#$P&)L5V\VLH->23Z]AN7H#FQ0<@:41;C$7H6!FDP031CIRA]I+"#%N
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M=R#,UJ9<3^$)]6?2QJ1%(R-A$Q\);QCV40')!7#L2T:6V[T Y]'SJ+P<2:7
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MJ*M@56BT5[PBF #(D>G,W$&0%327%@P9I<E(C(RT& AI&F78T27N:TBJ3TT
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M3J2.1G*WG::(OFJDCBBH+.5FW=0&T2@ZF;#-(FRY5_T7"]/:",9N_&9"JV_
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MPY_W-C?,?^"_]P?'R:"_]VORC\.C3^;9!_#QM^8;3@:'\-S^P<'OYJ6/$OC
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M+%Z*GT_+8I;1Q\/!65JE69',X691G3:X^.8LCI(&KEY'#6P)W@+>B"_!K\^
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MQ&?@@CQ-ZB9*,V(;=-B?6A?:S?)VOTE,[B]\Q<3.MG_'=;@1WL2Q@YYKST!
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M)#.-7:L3 ]<DW/4%;?)6UVO#[UEA<3YB4WNY6;2(,5)HQ=L.)'>BW21+&9<
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MS9+F2@7- 3#H*:Q^.#A)/J4Z.)2[YHAV<: =G: T:6]A3.<IW3)0+)IRY("
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MJG-(JD4T^#U].GI'%9&CE9KMJE!P6O:Y('H]-GBK7/HI%/0,P?5;$2(!MNV
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M+4.*9_(D+ZD!;@5(41IBB3TJU(A$F>G\3O,:K09' S2<[FXCEX((+LU/M@;
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MO=23@!4P0EC!( *JKNQ<HQZJMOK$]QU!E>MZUXTKC&48B@VR&FMN.T>8L$%
M'ZXU,!8"0W#QZW ZFW1J.E.! 8)YJ:E=:H#M]IIJ.>/2$+2S6BP23V_UT&.\
M%QE\:/@]LH3[>(1WHW6B:YD]/D6-%&$I,I)ADO(IS1HJ<-9W-_4U=<FFS+PJ
M^4P[C>>[FTWW2>RX3\ZYW>U(GI*+X7+&83E=L;RKTGE:50Z,53P.@S=V49%T
M,4KMNDD3@Q0+"3-F0B#*RK!#2C7$K.GQPR6.' ^%NTU@L8+HT0FFZ&"#4C!J
M@#T1*=>LS12DUF:BGT$=G[ V?J;@:'T"NR;,/\/!I9BG6QNH]]VE:01M+/!]
M,7N=>;)8$&?;N?0Z-MU>8;CV?E[SWP*T$ C!U3;9-.ITKK7%.P4,VGF1D0QT
MYI+4)EU@O30F*DR^V!%Y_'A;WYP9Y=:&4TY25^<T9L#=>!RDHC=I$E_@6%H-
M![W$"N4L4Z@V%*(.-T:)CGMMAIYN.Z8]V7#0E28V;W0&BS73)'?;:.D6Z14U
M^FW00DELM,0.-[\"M>Y/A<.@_8[&GX%);^ETKO: ,:#P&@]WJB$ U\E9:-<$
MT\&(*J4XDD3!+;>10E ;X2-NJ18VR<[3MM%*;B[-Y*$O]"D&LW[:%A2E3J-4
MEQ2M).M,H$I6A>%'6FCG-7=VB@I]/KB,=/1L&>;VW:(0'7P/]G-'\E6$3EAL
M7+8-^CZ)9H-P+YX?F/#>$4)=?OKVA1N':X=7.::Z1$E7932/11F3>E8"H:JT
M'2!#T6>%56<7->>D>W;K32F!P.IO# !+>QE?OR*(>O2 F2YV-8H@;>N!C0Z%
M!%PL;=2ZWD &>[@,*>R >[?!M (-'-J9-K45'5IL"\<!.#ZGXV@T+?.<<3[Y
MVI]/U&)HV,2BSG 4,(<$+'MOU47=1_)F==$EE/15Z**@-J(+-D:N9*L)L%M5
MFW1Y]SRS!UY@;9NNEU4P/:?NK<UP=8:/^Y>@@A2Q43\\K@:06@"4*CT48_AO
MP##U-GU*,1ZBXKEIT'3 0I<D;=%496<'58?3;&V*$R5_\K Y"\M9VC?VA?)(
MG+&6QZ+MG6P#5(?KR%-SEH/3YI)UJ_(OUNK!.1)Q]'0<O5C5")^M:9I/[2Y4
MWW,D07LLEJW,4)@ EZ?R-7PY\K-:K0TI+$H)Z.,I=B>LHU_1IS9.D^EJX76-
MZ"M:[EU1#[U-;VGINO^C*0>+$>?D@3JRGO?2?@/.!*ZP^G6JC[.BD:9$H:8]
M;T&H;9^?%R4>=7C4(?5E*RL0QE[XOBPH%],)OS1\X!2QXC\A-\7.I' EEZMQ
M&;S<0S_CLS;K)0EUD@YR!R.9P2HI3&<ZNMQ"9<?F-'6P@?'?=MA\WB<[E+%$
MA)X4=U%+/>$VQV+S$</!N$IWD("T+NC<_]@I\$^:X,5M*P)#&#^U2P@Z!ZO:
MJ+E.'?SUOJF'NFN9EUAWI0-X2S'1/3: 4T<Q:SBV!8?N<#EU>Z-ZQB?P2Q,G
MR%L[)R6:KRI<IV[ O)?$N%9D?-T:K'/'G6$B!.OH%9'T0=\C%#%HNS20RC=S
M\SSGML^1Y3()/E5KK;]SF .;>>C N^YECOO?X#(PGQ_N83ZW".9S"T$^\QO-
MQ]FR--LUA_$]P\$^34BV?W;#G,; "[JSFM[$Z'PTQ!#::D'_]NA;X MLZF::
M.G>U@H#G;VR:\63'7F1>;Q<)6U)1BCNI3Z;/L]"=F1%JV.>)%=QJH9+E2@IH
MNM=Q!PH83F\Z6<QM>RBTPV;2M95*7OVL\RLD@ZT5)5+X14:<./_M+"U2'408
M5"%E3L32GR^V=KS'GB/F!92XQ<VR<<:'^+F#"4X&F)*71]8C&OLYM@'F2&.[
MP4JP5,='<>JA*$U%HV01D<$I<_MI*TL8-B8N9L&#DVA2X> 4.VE<CC?ZN=K&
MR]@"]E'7 >>XW<-,G .XCP:2-X+7.9)8BANT"@H0GA;!:-HC=& [:7P5; IR
M%EJT.@F3^F8[:$T>W=[_+)J@DR!ZI*@P\,5]B;%[OT674AT90I5FZ<*;Y!4\
MZF!L5N \*UDU9V4%A*>O4*&!N.34",M:L^$=S?B3RH;3* !"P;,)!X-+)[)F
ML59DK[>J29V:G4I_KZ0 8W0XUH@4'/0D-]@MM]8O<)3:8Z&Z7"<^CS[^M)N
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MUE2:+=O#J^:F,X=3=3,<A&4WMJ]-C@O$GW!],W]]"V]]?B5%98$?P)E5PRE
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M]]%F7P++:2EVX5H0R-%90NW"E2%5Z>@5I/_QFCNPC_FU[R-UU3D/6Y7^AKN
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M\!94/> +=(O()&6W(QN0Y]AJ?1?,MH*4LAJ@M&#U%^9JD5;8 =3W,K/T6!C
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MTN.W/6.OWB=MZ-WR(M_>&J/#4 P=HR9X.EO/>#S40]O=5#OL$]R-8.@E)?R
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MB]P1-A2NPY3<[WV"#7%2C?5CJRO"2F_1.\#5SR$_L&7 -39MP]M<NEPZ6CN
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MXE CJ/R)D7(,B#[2XA!3IC8?NOC+.5A>A:_<372'#XB6,T$CIE<<"OH8X/N
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M1T*O#CM0PC%"1MHU.I62I/[&3-[E7BWB\Y@I,4LJW+))EBGY2[(=.Y_,ZB_
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M.3N72N34<[A'31?D!991,2] BF5B.:18W=!>$ZM'W &3?:'=<W17!QA;(W5
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M!LFPLWJ^7G\UR]19GBO"732X"5:-ZVS: S8)=Y(G\8MK<5)D(AYNZAYYC-P
ME6(@3\-@7Z!&O!PL-@T_1!UX)U?T W$$$@-[F2'@U!#9@X%E@"X0ZT=BAZ1)
M[@?% &GBV;X)"BD34F,6VK,(;5<4EZ-Q!M*#Q2@K(&+C<-NABEI)TSW2I!H6
M%S7Z$G%(Q@"+0(R8=WN7CL=\*QO9,BT$U+%4&(8L ^Q!N\#5PNFN!DXW][K?
MT;E$K@-(86,0LP2 @%731$9C1;L[ QG;9N: Z?C"RG_IT'ZSOM:P\C)\P>RW
M*I)GE$NJ6D;<-X#08M)#"-MV^_' ))!O7UUDD:8T&.0PRB$@03'NBNN8>] ]
M-,ZD2[F.+]&8ZVM 4]//TX5>1B2BTKXF(8B,JBD^ "78"EP>R@>DQX26V,PK
MH2*-#'_?L;A(%:J@UP).7E]+\6FD]R.4ES[L@A+U%5V/J,QQ*2@58-R<U<O9
MH+&8*QC<Y"@)-@+SSU8UJRC*BDGO43 F<R-R^"8JL#["-9KI<DI#!_;8D\SL
M3K-):#F!)[@@:$BEKH>6'Q-V$#..@_&3%A?X5L=B:BV*=(,9LGY<$JFUKO^B
MU$@, 5/\SU:^0H; J<#9DHU#/U>\(,7C^?$$(N[:N9 ZV!US(-@/KI1BZ.C:
M%O>W>6LYUT);RH3!B@OOJ@R<<) "^[6^%G.*V$AEMBO5$W@M=F"??%4 [LG0
M=D/WG4]&-4C9@=[5D5,$;;&G-&=1]H+(8Q#XO;XF'X@OV8')16\2J5[WW1C)
M^F[,/B/1Q<3,[%-QB -0!=#=4$<7>E@PBCA_H:HL>\19:7 .@TY9&)BLKX5,
MZ"^RXJ)[=)E,6 E:I&9;F,@B]80T8R>PNQHZQ7%>B:?E*+*-X#6/@U=DVX;4
M;3)==PO6.W)R)\^3<?[PG"NZ<RV98&LUHNR:S'Q6 B<L\N<F=2(?,*-W?QQ0
M)AOR:C=P.\KE<JZT62G6RZ^S,>@UIAH4D0&N =K_&Q9@ R##J78AZ#9(L2Z!
M6O'?/?R'1X-\.EY=7_-9,'MWZ!1Z/"D>/-HZR6P4:Q6$+N.DDB]FX3\E,;*H
MX"]?.0(MC7%6JE0==$G#ST3Y'^L(V*26.Y"&$0UQWQ('NMX0,*&'848B8 68
M-/\C%#(O&,4*60'$#P^OG?+OC(<!NB-<1(>Y8^"M+"A6#Y@OG"/@1IPJNI\1
M1@] 2&$&8,?P"W\K]KN'_0QPL0UBV;J).@&I 8X]]YWF0T^U^/68[#F6=0W+
MD\/#4\"M0:7O)DUO+)[4^12_D6J^&' 4F<U08F7Q$OJ"]+SC\+>4?OB;>A1=
MBHZB[_TZW.:??0*\.@=?G8,_]!R\G%=*3W8.?F'&SC([05*K!>XVV(G(B_H[
M#\'/Y8T?!O"'.! TPR^A@_F$*!73. .TKV$]0UB7>(=6GM3(<54LC37TB#A#
M> 51BC@>)ZVO">?4"*/VNPY?T.?&+'^,WC,O&_!K.;-H<^A05JLE_.6P.\2&
MJAL='&,R(?(\,*:2 2':0;E:4(=6V:"O-TJOT485L"24]3U#^M#-] )3'Q'1
M,[$C.;T?HB5<\?3ETFM7NTQF];$I/'G"(!!]I-B2$R&*ILOB/MV\L8P;B)/#
ME)_M=8%KPEQ)-CQ(3%34S@5<EF@>"_P"W00_#X\^7"Q7D3>?B7L F<,QBO4A
MT;!24?J,48R;)<C;P2(A:" CIBEGB3\7SD.T0 P)?N"6S.,$J!!8=^FU.&8,
MYA+02/]2=V6P1\E [P_2%Q !WT1S4,O!,76+-P_I<DN)<Z0!U?P,DLHXIZ+
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MH@  L$4#  H              ( !     &5X,3!?,2YH=&U02P$"% ,4
M"  /B*54FB>Z.6)-  #7K $ "0              @ &OH@  97@T7S$N:'1M
M4$L! A0#%     @ #XBE5!!,B0P73   B*@!  D              ( !./
M &5X-%\R+FAT;5!+ 0(4 Q0    (  ^(I50-H_;3'0P  (0M   )
M      "  78\ 0!E>#5?,2YH=&U02P$"% ,4    "  /B*54>9NC,@,-   L
M*@  "@              @ &Z2 $ 97@Y.5\Q+FAT;5!+ 0(4 Q0    (  ^(
MI51(; U00@,   H,   1              "  >55 0!M;V1D+3(P,C(P-3 R
M+GAS9%!+ 0(4 Q0    (  ^(I51^!V)3_PH  &R'   5              "
M 599 0!M;V1D+3(P,C(P-3 R7VQA8BYX;6Q02P$"% ,4    "  /B*54F^="
MGED'  #/6   %0              @ &(9 $ ;6]D9"TR,#(R,#4P,E]P<F4N
M>&UL4$L! A0#%     @ #XBE5+);Q6.;&@  2[$   X              ( !
H%&P! &UO9'5L87)?.&LN:'1M4$L%!@     )  D %@(  -N& 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
